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Abstract
Aims To determine whether IHC4 score assessed on pre-
treatment core biopsies (i) predicts response to neo-adju-
vant chemotherapy in ER-positive (ER?) breast cancer;
(ii) provides more predictive information than Ki67 alone.
Methods 113 patients with ER? primary breast cancer
treated with neo-adjuvant chemotherapy at the Royal
Marsden Hospital between 2002 and 2010 were included in
the study. Pathologic assessment of the excision specimen
was made for residual disease. IHC4 was determined on
pre-treatment core biopsies, blinded to clinical outcome, by
immunohistochemistry using quantitative scoring of ER
(H-score), PgR (%) and Ki67 (%). Determination of HER2
status was made by immunohistochemistry and fluorescent
in situ hybridization for 2? cases. IHC4 and Ki67 scores
were tested for their association with pathological complete
response (pCR) rate and residual cancer burden (RCB)
score.
Results 18 (16%) of the 113 patients and 8 (9%) of the 88
HER2-ve cases achieved pCR. Ki67 and IHC4 score were
both positively associated with achievement of pCR
(P\ 10-7 and P\ 10-9, respectively) and RCB0?1
(P\ 10-5 and P\ 10-9, respectively) following neo-
adjuvant chemotherapy in all patients. Rates of
pCR?RCB1 were 45 and 66% in the highest quartiles of
Ki67 and IHC4 scores, respectively. In ER?HER2-ve
cases, pCR?RCB1 rates were 35% and in the highest
quartile of both Ki67 and IHC4. There were no pCRs in the
lower half of IHC4 or Ki67 scores.
Conclusions IHC4 was strongly predictive of pCR or near
pCR in ER? breast cancers following neo-adjuvant
chemotherapy. Ki67 was an important component of this
predictive ability, but was not as predictive as IHC4.
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Introduction
The EBCTCG overview of clinical trials comparing adju-
vant chemotherapy with neo-adjuvant chemotherapy in
patients with primary breast cancer indicated that the
benefit of chemotherapy is related to absolute risk. The
potential benefit of chemotherapy in estrogen receptor
(ER)-positive disease is therefore related to the residual
risk on appropriate endocrine therapy [1]. Accurate deter-
mination of prognosis on adjuvant endocrine therapy and
identification of patients at sufficiently low risk who might
be spared adjuvant chemotherapy have been the priority
area of recent research [2].
IHC4?C is a composite score incorporating immuno-
histochemical parameters ER, progesterone receptor (PgR),
HER2 and Ki67 (IHC4) with a clinical treatment score
(C) of tumour size, grade, nodal status and type of endo-
crine therapy developed on samples from the TransATAC
cohort [3]. IHC4?C has been shown to provide similar
amounts of prognostic information to that provided by the
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21-gene recurrence score Oncotype DX, which has been
approved by the National Institute for Health and Care
Excellence (NICE) in the UK for guiding chemotherapy
decisions in lymph node-negative ER breast cancer deter-
mined to be at intermediate risk of recurrence using stan-
dard clinical variables [3, 4].
A recent decision impact study reported that the use of
IHC4 ?C was associated with a reduced use of adjuvant
chemotherapy in borderline cases where the benefit of
chemotherapy was considered uncertain by clinicians using
standard clinical variables [5]. Optimal clinical decision-
making incorporates the use of both prognostic markers,
which identify risk of recurrence together with predictive
markers, which identify benefit from a particular therapy.
Oncotype DX has been shown to predict the magnitude of
chemotherapy benefit in tamoxifen-treated patients in the
NSABP B20 trial although this study was limited by its
small size, the overlap in the test set with the training test
for Oncotype DX, and this being a secondary analysis [6].
The opportunities to assess the ability of prognostic
scores to predict benefit from chemotherapy in the adjuvant
setting are very limited because of the absence of good
sample sets from randomized studies with a no
chemotherapy arm.
The neo-adjuvant setting is an opportunity to obtain
some analogous data for chemotherapy benefit. pCR fol-
lowing neo-adjuvant chemotherapy is established as an
intermediate marker of long-term outcome, although ER-
positive (?) breast cancers are far less likely to achieve a
pCR [7–9]. In a small study of patients with locally
advanced breast cancer, a higher 21-gene recurrence score
predicted for pCR (P = 0.005). pCR was more likely with
higher expression of proliferation-related genes and
immune-related genes and with lower expression of ER-
related genes [10]. However, no such data for IHC4 have
been reported.
More recently, characterizing residual disease following
neo-adjuvant chemotherapy beyond simple dichotomous
classification of pCR or not has been described as the
residual cancer burden (RCB) Symman’s et al. [11, 12].
This score has been shown to be prognostic and its per-
formance is enhanced by its combination with post-treat-
ment Ki67 to form the residual proliferative cancer burden
(RPCB) [11, 12]. ER? disease in particular has been
associated with a favourable long-term outcome even in the
presence of minimal or minimal proliferative disease fol-
lowing neo-adjuvant chemotherapy, i.e. low RCB or RPCB
[12].
The development of these intermediate markers in the
neo-adjuvant setting provides an opportunity to study the
predictive role of pre-treatment biomarkers such as IHC4.
Given that so far the IHC4 score has only been shown to be
prognostic, the aims of this project were (i) to determine
whether IHC4 score determined on pre-treatment core
biopsies predicted response following neo-adjuvant
chemotherapy in ER? breast cancer; (ii) to determine
whether IHC4 provided more predictive information than
Ki67 alone, given that Ki67 has already been found to
predict for pCR.
Materials and methods
Patient cohort
A total of 113 ER? patients treated with neo-adjuvant
chemotherapy for primary breast cancer at the Royal
Marsden with pre- and post-treatment samples available
were included in the study (Online Resource 1). Patients
were identified retrospectively as a consecutive cohort
from a prospectively maintained hospital research database
between 2002 and 2010 [12]. Patients with stage IV disease
were excluded, as were those with insufficient pathological
material available for review.
Clinical and pathological assessment
Clinical assessment of the primary tumour and lymph
nodes was made according to WHO criteria using bi-di-
mensional caliper measurements of the primary tumour and
axillary nodes. [13]. RCB assessment was undertaken on
the post-treatment excision specimen as described previ-
ously to assess pathological response to neo-adjuvant
chemotherapy [12]. This involved assessment of the bi-
dimensional residual tumour bed, residual tumour cellu-
larity, and extent of lymph node involvement including the
number of lymph nodes involved and size of the largest
lymph node metastases [11, 12]. Immunohistochemical
staining was performed for ER, PgR and Ki67 on sections
on 4-micron sections of formalin-fixed paraffin-embedded
tissue from pre-treatment core biopsies as reported by
Cuzick et al. to determine IHC4 [3].
Statistical analysis
The primary objective of the study was to determine
whether IHC4 determined on pre-treatment core biopsies
was predictive of chemotherapy response. A secondary
analysis was to determine whether IHC4 provided more
prognostic information than Ki67 alone.
IHC4 was calculated according to the published algo-
rithm by Cuzick et al. [3]. ER was quantified by the
H-score and divided by 30 to arrive at a variable between 0
and 10 (ER10). PgR was quantified by the percentage of
cells staining positive, and this was divided by ten to obtain
a variable between 0 and 10 (PgR10). Ki67 was quantified
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as a percentage. As was described in the independent
validation cohort, the Ki67 percentage was multiplied by
0.4 to scale for the difference between the image analysis
technique used in the original development of IHC4 and
manual scoring [14]. This was because Ki67 scores are on
average 2.5 times higher with manual reading than using
the image analysis method from which the algorithm was
derived. HER2 was scored as positive if 3? by IHC and
equivocal 2? samples underwent fluorescent in situ
hybridization analysis and were considered positive if the
ratio was two or more.
Results
Patient demographics and treatment
Baseline patient demographics are shown in Table 1. All
113 cases were evaluated for IHC4. Of these, 18 (16%) had
achieved a pCR. Median age was 49. Almost all had T2
tumours or greater with just over half being clinically node
positive at presentation. Fifty-six percent were grade 2,
37% grade 3 and 19% were HER2 positive. Treatment
details are summarized in Table 1. Ninety-seven percent
received a neo-adjuvant anthracycline and 66% received a
neo-adjuvant taxane. Thirteen of the 22 HER2? cases
received neo-adjuvant trastuzumab. The majority under-
went breast-conserving surgery. Median follow-up was
5.1 years and there were 26 relapses and 20 deaths.
Response to neo-adjuvant chemotherapy
The relationship between pCR and RCB and long-term
outcome in this ER? cohort is shown in Online Resource
2. Outcome was significantly correlated with RCB class;
those with RCB class 3 residual disease had a significantly
poorer outcome following neo-adjuvant chemotherapy.
This confirmed the expected relationship between RCB and
long-term outcome in this cohort.
Pathological response according to pre-treatment IHC4
score and Ki67 is shown for all cases and for HER2-neg-
ative cases in Figs. 1 and 2, respectively.
Eighteen (16%) of the 113 patients including 8 (9%) of
the 88 HER2-negative cases achieved pCR (Figs. 1 and 2).
Ki67 and IHC4 score were both positively associated with
achievement of pCR (P\ 10-7 and P\ 10-9, respec-
tively) and pCR?RCB1 (P\ 10-5 and P\ 10-9,
respectively) following neo-adjuvant chemotherapy in all
patients. In the highest IHC4 quartile, 52% achieved a pCR
and 66% achieved either a pCR or minimal residual disease
(RCB 1). In the highest Ki67 quartile, 38 and 45%
achieved pCR and pCR?RCB1, respectively (Fig. 1). In
the sub-group of ER?HER2- cases where IHC4 would be
Table 1 Baseline patient characteristics and treatment details
(N = 113)
Characteristic Total (n) %
Age Median 49
Menopausal status
Pre 65 58
Post 34 30
Unknown 14 12
T stage T0
T1 1 1
T2 0 0
T3 63 56
T4 31 27
Unknown 14 12
N stage
N0 49 44
N1 60 54
N2 1 1
N3 1 1
AJCC stage
1a 0 0
1b 0 0
2a 38 34
2b 39 35
3a 19 17
3b 13 11
3c 2 2
PgR status
Negative 27 24
Positive 73 65
Unknown 13 12
HER2 status
Negative 89 79
Positive 22 19
Unknown 2 2
Grade
I 5 4
II 63 56
III 42 37
Unknown 3 3
Histology
IDC 101 89
ILC 10 9
Mixed 2 2
Other
Surgery
Breast conservation 63 56
Mastectomy 50 44
Unknown
Neoadjuvant therapy
Anthracycline 110 97
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most applicable in clinical practice, 30% of the highest
quartile achieved pCR and 35% pCR?RCB1. In the
highest quartile for Ki67 in HER2- cases, 26 and 35% were
achieved in pCR and pCR?RCB1, respectively (Fig. 2).
There were no pCRs in the lowest quartile of IHC4 or Ki67
for all cases or HER2- cases.
Higher Ki67 score was associated with a numerically
higher incidence of complete clinical response with the
75% of cases with a Ki67 in the highest quartile attaining a
complete clinical response. The relationship with partial
clinical response was less clear as was the relationship
between IHC4 score and clinical response (Online
Resource 3).
Relationship between IHC4 and outcome
There was a weak but statistically significant correlation
between pre-treatment IHC4 score and post-treatment RCB
score [Pearson’s R = -0.27 (P = 0.04)].
The relationship between the pre-treatment IHC4 score
and long-term outcome in this chemotherapy-treated cohort
is shown in Online Resource 4. There was a trend towards
shorter TTR being associated with higher IHC4 quartile
although this was not significant(P = 0.24) and impor-
tantly IHC4 has only been validated as a predictor of long-
term outcome in patients not treated with chemotherapy.
Table 1 continued
Characteristic Total (n) %
Age Median 49
Taxane 75 66
Trastuzumab 13 12
Adjuvant taxane 11 1
Adjuvant endocrine therapy 111 98
Fig. 1 Pathological response according to IHC4 and Ki67 quartile for
all cases (N = 113)
Fig. 2 Pathological response according to IHC4 and Ki67 quartile for
HER2-cases (N = 88)
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Discussion
In this cohort of ER? patients treated with neo-adjuvant
chemotherapy, a high IHC4 score was strongly predictive
of a pCR or near pCR (RCB1). Ki67 was an important
component of this predictive ability, but IHC4 provided
greater information. Whilst IHC4 has previously been
shown to be prognostic, this study now demonstrates the
relationship between IHC4 and response to chemotherapy.
Both Ki67 and IHC4 were strongly predictive of pCR
(P\ 10-7 and P\ 10-9, respectively).
A higher IHC4 score is associated with a poorer long-
term outcome in the patients treated with adjuvant endo-
crine therapy alone, but in this chemotherapy-treated
cohort baseline IHC4 did not show the same relationship.
This indirectly suggests the hypothesis that chemotherapy
benefit is focused to the group of patients with high IHC4
scores.
The relationship between other multigene signatures
associated with prognosis in ER? breast cancer and
response to neo-adjuvant chemotherapy has also been
examined by others. Oncotype DX has been tested in the
neo-adjuvant setting and found to be associated with pCR
(P = 0.005) [10]. Other signatures have also been associ-
ated with better response to neo-adjuvant chemotherapy
although not necessarily survival benefit [15–18]. The EP
signature was specifically tested in ER?, HER2- tumours
where the benefits of chemotherapy are less certain. EP
classification was associated with a pCR rate of 7% and in
the low-risk group and 17% in the high-risk group
(P = 0.001) with EP score significantly associated with a
pCR [15]. The Prosigna risk of recurrence score (ROR) has
also been shown to be correlated with response to neo-
adjuvant chemotherapy in ER? HER2- breast cancer.
This includes a proliferation score, which was also strongly
associated with response [18]. The findings in this study
that a higher IHC4 score is associated with a higher rate of
pCR are therefore consistent with other reports that patients
at higher risk, as estimated from molecular profiles,
respond better to chemotherapy.
Higher pre-treatment Ki67 was also associated with a
greater likelihood of pCR but not all studies have shown
Ki67 to be an independent predictor of pCR [19]. This may
in part relate to analytical variability between labs assess-
ing Ki67. Reports have examined the relationship between
pre-treatment Ki67 in predicting benefit from adjuvant
chemotherapy. Ki67 alone has not been shown to predict
benefit of adjuvant cyclophosphamide/methotrexate/fluo-
rouracil chemotherapy to adjuvant endocrine therapy in
lymph node-negative patients [20]. Other studies have
examined the potential of baseline Ki67 to predict benefit
from specific regimes reporting a trend towards benefit
from the addition of taxanes to anthracycline-based
chemotherapy [21, 22].
A limitation to the assessment of chemotherapy benefit
in ER? disease in the neo-adjuvant setting is the hetero-
geneous outcome associated with residual disease, with
pCR being a stronger predictor of long-term outcome in
ER- or HER2? disease [23]. In the current study,
achievement of minimal residual disease (RCB class 1)
was also assessed as this has been shown to be associated
with excellent long-term outcome. However, further vali-
dation studies are required to define clinically useful cut-
offs of risk for RCB in ER? and ER- disease.
Ki67 scores in the highest quartile were associated with
a 75% complete clinical response rate; however, there was
no clear association between the IHC4 score in predicting
clinical response to neo-adjuvant chemotherapy. Clinical
response to neo-adjuvant chemotherapy is accepted to be a
poor correlate of chemotherapy response, and this study
was underpowered to address this question fully with
complete information on clinical response only available in
85% of cases.
This study was limited by its relatively modest size and
single institution, retrospective design. Thirty percent of
cases assessed for RCB did not have pre-treatment samples
available for analysis due to a significant proportion of cases
being diagnosed at outside centres (S1). Nonetheless, RCB
related to long-term outcome as expected and therefore this
cohort may be fairly considered as representative of a con-
temporary ER? neo-adjuvant population. The pathological
work-up and reporting of residual disease was rigorous and
allowed reconstruction of the residual tumour bed for
assessment of RCB. The quantitative assessment of ER,
PgR, and Ki67 were performed in a laboratory with exten-
sive experience of conducting and assessing these results for
standardized input for the IHC4 algorithm and the rela-
tionships of both Ki67?IHC4 were very strong. Efforts are
ongoing to standardize IHC4 for wider adoption into clinical
practice [24]. In conclusion, both pre-treatment Ki67 and
IHC4 were positively and strongly associated with
achievement of pCR with a greater association with IHC4
than pre-treatment Ki67 alone. These findings provide sub-
stantial support for IHC4 measured at baseline prior to neo-
adjuvant chemotherapy providing predictive information on
the responsiveness of tumours to chemotherapy.
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